Publications
TCR T Cells, VST Cells
Publication Date: April 29, 2022
Combining IFN-γ cytokine capture with retroviral transduction allows virus-specific T cells carrying a survivin-specific TCR and CD8αβ to be generated from healthy donor blood in about ten days. PBMCs were stimulated with CMV and EBV peptide mixtures, IFN-γ-secreting cells were isolated, cultured for 3 days and transduced. Transduction reached 66% mTCR-positive cells, and expansion averaged 269-fold in 10 days, with products predominantly CD8+ and rich in central memory cells (81%). Transgenic cells kept anti-viral reactivity while gaining survivin-directed IFN-γ production and killing of BV173 leukemia cells (residual tumor cells 0.04 vs 2.3 × 10^6 with non-transduced cells). Yield of IF…
Publications
CAR T Cells, TCR T Cells
G-Rex®24 Well Plate
Publication Date: April 22, 2022
A nonviral method using plasmid donor DNA and Cas9 ribonucleoprotein achieved efficient site-specific knock-in in primary human T cells. Nanoplasmid donors at 4 μg gave 36.2–46.6% TRAC knock-in in CD8+ T cells with minimal effect on viability, about twice the edited cells obtained with pUC57 and three times that with linear dsDNA. Using nanoplasmids, 1G4 TCR knock-in reached 44.9–54% together with TRBC knock-out, and engineered T cells lysed 77–81% of peptide-pulsed targets at a 1:1 ratio. The approach also worked at AAVS1, RAB11A, CD4 and TNFRSF9 loci, supported dual knock-in, and integrated payloads over 5 kb with more than 20% efficiency. At day 7 in culture, knock-in cultures yielded…
Publications
TCR T Cells
Publication Date: April 14, 2022
Medigene investigators isolated a high-affinity, HLA-A2-restricted T-cell receptor against the cancer/testis antigen PRAME (TCR-027-004) from non-tolerized repertoires of healthy donors and co-expressed it in CD8+ T-cells with a chimeric PD1-41BB receptor that joins the PD-1 extracellular region to the 4-1BB signaling domain. T-cells were transduced twice retrovirally, then expanded for 10 days in G-Rex® flasks with IL-7 and IL-15 at 5 ng/mL twice weekly. Adding PD1-41BB increased IFN-γ release against PD-L1-positive tumor lines and preserved killing of 3D spheroids re-challenged on days 3, 7, 10 and 13 over 16 days, without altering functional avidity or healthy-cell recognition. In MelA…
Publications
CAR T Cells
Publication Date: April 13, 2022
Ex vivo culture conditions can substantially change the quality of CAR T cell products, yet they receive less attention than genetic engineering. This review examines how media, sera and serum substitutes, cytokines, pharmacological inhibitors, culture duration and cryopreservation affect CAR T cell expansion and function. Across the studies discussed, methods that preserve less differentiated, less exhausted or less glycolytic cells generally gave products with higher in vivo anti-tumor potency. For example, human platelet lysate supported expansion at low serum concentrations where fetal bovine serum failed, and IL-7/IL-15 outperformed IL-2 over time. Shorter manufacturing gave better t…
Publications
CAR T Cells
G-Rex®24 Well Plate
Publication Date: March 25, 2022
Fractionated irradiation followed by CD98hc-redirected UniCAR T cells had a synergistic antitumor effect against radioresistant head and neck squamous cell carcinoma spheroids in vitro. UniCAR T cells, switched on by a CD98hc target module, were cocultured with spheroids at a 5:1 effector-to-target ratio for 48 h. Killing required the module, with a half-maximal effective concentration of 250 pM, and that concentration increased T-cell infiltration into spheroids. Irradiation with 2 × 2 Gy before UniCAR T treatment eliminated Cal33 RR and FaDu spheroid cells more efficiently than immunotherapy or radiotherapy alone, and granzyme B upregulation persisted after irradiation. In TCGA data fro…
Publications
Other
Publication Date: March 17, 2022
Neutralizing monoclonal antibodies against Venezuelan equine encephalitis virus, isolated from immunized mice and one vaccinated human donor, protected mice from lethal aerosol challenge. Fourteen murine antibodies and one human antibody were grouped into three competition groups targeting domains A or B of the E2 glycoprotein, and they blocked attachment, fusion or egress. Cryo-EM of the human antibody hVEEV-63 bound to virus-like particles, resolved at 3.2 Å, suggested cross-linking of neighboring spikes. A single 100 μg dose given 24 h before challenge gave 70-100% survival. Given 24 h after challenge, domain A antibodies gave 50-70% survival and most domain B antibodies gave 80%.
Publications
CAR T Cells
G-Rex®24 Well Plate
Publication Date: March 10, 2022
The Tmod dual-receptor system, which pairs a CAR or TCR activator with an HLA-A*02-directed LIR-1 blocker, responds in a buffered, sublinear way to wide changes in antigen and receptor levels in vitro. Across a roughly million-fold range of blocker antigen, the MSLN CAR activator EC50 shifted about 100-fold, while blocker IC50 shifted about 20-fold over a 100-fold range of MSLN antigen; for a KRAS TCR activator, EC50 shifted at least 100-fold over a smaller range. Changing the activator:blocker receptor ratio by 3.5-fold (CAR) or 14-fold (TCR) altered blocker sensitivity only modestly. Jurkat reporter cells and primary T cells from two donors gave similar trends, and the data indicate a m…
Publications
Other, T-Cells, TIL Cells
G-Rex®100, G-Rex®100M-CS
Publication Date: March 9, 2022
The LOVO Cell Processing System, which replaces centrifugation with a spinning filtration membrane, gave satisfactory viability and recovery when four NIH-sponsored PACT facilities used it for final harvest or wash of T cells and mesenchymal stromal cells. Each site compared LOVO with its own routine method. For tumor-infiltrating lymphocytes, viable cell recovery was 78.3% on LOVO versus 66.7% on Cell Saver 5. For bone marrow MSCs harvested at Minnesota, viable recovery was 80.0% versus 70.3% on the Cobe 2991. Activated T cell viable recovery was similar (91.1% manual versus 90.4% LOVO), and Miami's post-thaw MSC wash was faster on LOVO (40-45 versus 100 minutes). LOVO took longer at sev…
Publications
NK Cells
G-Rex®24 Well Plate, G-Rex®6M Well Plate
Publication Date: March 7, 2022
A feeder-cell-free, fetal-bovine-serum-free protocol combining NK Cloudz microspheres, a G-Rex®6M well and GMP human platelet lysate expanded natural killer cells 387 ± 100-fold in 10 days from peripheral blood mononuclear cells. Starting from 500,000 NK cells in 100 mL of medium per well, cultures reached 71% ± 15% NK purity and 89% ± 3% viability, averaging 198 ± 61 million NK cells per well. Platelet lysate performed comparably to 10% FBS (300 ± 57-fold), with similar cytotoxicity against K562 targets (57% vs 58%). A flask-based K562 feeder-cell protocol gave 671 ± 385-fold expansion, not significantly different, but needed handling every 2–3 days. A split-and-transfer variant reached…
Publications
VST Cells
G-Rex®6 Well Plate
Publication Date: February 14, 2022
T cells specific for SARS-CoV-2 can be expanded from a small panel of convalescent donors and recognize cells infected with several viral variants. From 60 convalescent individuals screened, 12 were chosen for their CD4 and CD8 responses and broad HLA coverage. Peptide-stimulated blood cells grew a median 18.4-fold over 14 days in G-Rex® vessels with IL-2, yielding mainly CD4 T cells with polyfunctional cytokine profiles and cytotoxic activity against HLA-matched targets. Analysis of HLA restriction suggested 97.15% combined worldwide HLA coverage. Of 22 defined epitopes, three carried amino acid changes in Omicron. Donor Q-029 T cells released IFN-γ after exposure to cells infected with…
Publications
NK Cells
Publication Date: February 14, 2022
Third-party, HLA-disparate NK cells expanded ex vivo on an mbIL-21 feeder line were given safely to nine adults after lymphodepletion, with no graft-versus-host disease and no dose-limiting toxicity. In a 3 + 3 phase I trial, each patient received two infusions two weeks apart at 1 × 10^7, 2.5 × 10^7 or 5 × 10^7 cells/kg after cyclophosphamide and fludarabine, without exogenous cytokines. Six patients had colorectal carcinoma and three had MDS or AML. Donor NK cells persisted at low levels for up to 28 days, making up 1% to 3% of circulating PBMCs at day 28. One MDS patient reached complete response with incomplete platelet recovery, and three other patients had stable disease through day…
Publications
CAR T Cells
G-Rex®6 Well Plate
Publication Date: February 7, 2022
Autologous rhesus T cells engineered with an SIV-specific CAR and the follicle-homing receptor CXCR5 reached B cell follicles in SIV-infected macaques and were associated with lower viral loads, with no observable adverse effects. The studies used 10 macaques; ART-suppressed animals received 0.8–2.0 × 10^8 cells/kg at the moment ART was stopped. The cells divided in vivo, were present in a median of 96% of lymph node follicles at 6 days after infusion, and were undetectable in sections by day 60. Five of six treated animals had lower viral loads one month after infusion, and two kept loads below 10^4 copies/mL throughout. Groups were too small for statistical comparison.
No manuscripts match your filters.